Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Trial Profile

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRESENT
  • Sponsors Galena Biopharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Nov 2016 According to a Galena Biopharma media release, management will present the top-line data from the trial and its assessment of the results in conference call.
    • 09 Aug 2016 Company has initiated an investigation into the causes of the the Independent Data Monitoring Committee (IDMC) recommendation to stop the trial, according to a Galena Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top